Johnson & Johnson reports data from Phase II prostate cancer trial

Johnson & Johnson has released results from a Phase II clinical trial evaluating ERLEADA (apalutamide) as an adjuvant therapy with androgen deprivation therapy (ADT) in high-risk localised prostate cancer (HRLPC) patients post-radical prostatectomy (RP).